Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 oct. 2022 08h30 HE | Source: Longeveron

Longeveron to Present at the Annual Dawson James Small Cap Growth Conference

MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
15 sept. 2022 08h30 HE | Source: Longeveron

Longeveron Names Jerome Bailey Vice President of Business Operations

MIAMI, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has...
06 sept. 2022 08h30 HE | Source: Longeveron

Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference

MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
31 août 2022 08h30 HE | Source: Longeveron

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants

MIAMI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
25 août 2022 08h00 HE | Source: Longeveron

Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker

MIAMI, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening...
12 août 2022 08h00 HE | Source: Longeveron

Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

—Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment – Japanese Pharmaceuticals and Medical Devices...
08 août 2022 08h30 HE | Source: Longeveron

Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022

MIAMI, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
07 juil. 2022 08h00 HE | Source: Longeveron

Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)

MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening...
13 mai 2022 08h00 HE | Source: Longeveron

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

MIAMI, May 13, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and...
09 mai 2022 16h15 HE | Source: Longeveron

Longeveron Announces CEO Transition

-Geoff Green stepping down as CEO, effective June 1, 2022 -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed Interim CEO -Nationwide search is underway for permanent CEO MIAMI,...

Page précédente